Evidence map›Paper›PMID 34854949›Full record

ArticleCancer immunology, immunotherapy : CII2022

MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues.

Tony Yao, Patrick T Rudak, Céline M Laumont, Alex R Michaud, Rasheduzzaman Rashu, Natasha N Knier, Paula J Foster, Hamish E G McWilliam, Jose A Villadangos, Brad H Nelson and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Tony Yao *Department of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, Canada.
Patrick T Rudak *Department of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, Canada.
Céline M LaumontDeeley Research Centre, BC Cancer, Victoria, BC, Canada.
Alex R MichaudDepartment of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, Canada.
Rasheduzzaman RashuDepartment of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, Canada.
Natasha N KnierDepartment of Medical Biophysics, Western University, London, ON, Canada.
Paula J FosterDepartment of Medical Biophysics, Western University, London, ON, Canada.
Hamish E G McWilliamDepartment of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Jose A VilladangosDepartment of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Brad H NelsonDeeley Research Centre, BC Cancer, Victoria, BC, Canada.
Gabriel E DiMattiaDepartment of Biochemistry, Western University, London, ON, Canada.
Trevor G ShepherdThe Mary & John Knight Translational Ovarian Cancer Research Unit, London, ON, Canada.
S M Mansour HaeryfarDepartment of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, Canada. Mansour.Haeryfar@schulich.uwo.ca.ORCID http://orcid.org/0000-0002-1125-8176
Western University · CAThe University of Melbourne · AUUniversity of British Columbia · CA

Funding

Australian Research Council 170102471Australian Research Council DE170100575Canada Foundation for Innovation 36239Canadian Cancer Society 706396CIHR 427647CIHR 429161Michael Smith Foundation for Health Research RT-2020-0630National Health and Medical Research Council 1058193National Health and Medical Research Council 1113293National Health and Medical Research Council 1117017
6 · The paper itself

Abstract

The low mutational burden of epithelial ovarian cancer (EOC) is an impediment to immunotherapies that rely on conventional MHC-restricted, neoantigen-reactive T lymphocytes. Mucosa-associated invariant T (MAIT) cells are MR1-restricted T cells with remarkable immunomodulatory properties. We sought to characterize intratumoral and ascitic MAIT cells in EOC. Single-cell RNA sequencing of six primary human tumor specimens demonstrated that MAIT cells were present at low frequencies within several tumors. When detectable, these cells highly expressed CD69 and VSIR, but otherwise exhibited a transcriptomic signature inconsistent with overt cellular activation and/or exhaustion. Unlike mainstream CD8

Indexed as

Mucosal-Associated Invariant T CellsOvarian NeoplasmsAnimalsAscitesCarcinoma, Ovarian EpithelialCD8-Positive T-LymphocytesCuesCytokinesFemaleHistocompatibility Antigens Class IHumansInterleukin-17LigandsMiceMinor Histocompatibility AntigensCytokinesHistocompatibility Antigens Class IInterleukin-17LigandsMinor Histocompatibility AntigensMR1 protein, humanMr1 protein, mouseAscitesiNKT cellsMAIT cellsMR1Ovarian cancerVISTA

Identifiers

PMID34854949
PMCPMC10991590
OpenAlexW3215213683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.